Workings of the SNM Clinical Trials Network Centralized IND for FLT
Download
1 / 20

George Q. Mills, MD, MBA Vice President, Medical Regulatory Relations Perceptive Informatics - PowerPoint PPT Presentation


  • 131 Views
  • Uploaded on

Workings of the SNM Clinical Trials Network Centralized IND for FLT. George Q. Mills, MD, MBA Vice President, Medical & Regulatory Relations Perceptive Informatics. Discussion today includes background information, comments and references to the SNM Clinical Trials Network Centralized IND

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about 'George Q. Mills, MD, MBA Vice President, Medical Regulatory Relations Perceptive Informatics' - royal


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript

Workings of the SNM Clinical Trials Network Centralized IND for FLT

George Q. Mills, MD, MBA

Vice President, Medical & Regulatory Relations

Perceptive Informatics


Discussion today includes for FLT

background information, comments and references to the SNM Clinical Trials Network Centralized IND

Selection of [F-18] FLT: an Investigational,

non-FDA approved, PET Imaging Agent


FDA / IOM Meeting – October 2007 for FLT

Therapeutic Drug Developers Comments

  • PET imaging desired for Multi-center Therapeutic Trials …but ... numerous deficiencies with PET imaging

    ISSUES

    • Lack of qualified & experienced imaging centers for large (200+ sites) multi-center Phase 3 clinical trials

    • Limited supply of known/desired investigational PET agents

    • No standardized PET imaging acquisition protocols

    • No harmonized PET imaging report output

  • Industry could not effectively implement PET imaging in multi-center therapeutic clinical trials


SNM Assessment Efforts for FLT

Multiple Discussions:

  • Therapeutic Developers

  • Participating PET Imaging Centers

  • FDA: Pre-IND Process

    Results:

  • Multiple IND Design Solutions

    • Regulatory

    • CMC

    • Imaging Standardization


Solution Topics for FLT

  • Clinical Trials Network (CTN) Sites Registry

  • Selection of IND biomarker – [F-18] FLT

  • Distributed Manufacturing of PET agents – CMC

  • Imaging Standardization


Topic 1: Clinical Trials Sites Registry for FLT

  • International Registry - Investigators’ Sites

    • Industry necessity & reality

    • “Pick list” to match therapeutic sites

  • Criteria to enable industry review & site selection

    • Enrollment & qualifications

    • Location

    • Equipment – hardware & software

    • Personnel

    • Access to investigational imaging agents

    • Participation: phantom program – clinical trials



Areas for FLT

of

Interest

  • Selection: [F-18] FLT (Oct. 2008)

Topic 2: Centralized IND Selection

8


Selection Criteria for [F-18] FLT for FLT

  • Investigational PET imaging biomarker

  • Literature reports of “potential” for demonstrating tumor proliferation

  • Potential as a surrogate marker for evaluating investigational oncology therapeutics as well as existing therapeutics

  • Broadly applicable for lung, breast, esophageal, GI, brain, lymphoma

PRE-TX

22 days

113 days


Topic 3: Distributed Manufacturing of PET Agents for FLT

Distributed Multicenter Manufacturing of PET Imaging

  • FDA: Anticipates “single GMP product”

    • PET production

      • Multicenter methods of production of the investigational PET product

      • Multiple “similar” PET products by end-product specifications


Using the SNM Centralized IND for [F-18] FLT for FLT

  • FDA must review CMC for all manufacturing sources & methods

  • CMC from all manufacturers supplying [F-18] FLT to trials must be submitted directly to IND or through letter of cross-reference to a filed DMF

  • FDA defines acceptable ranges for [F-18] FLT by end-product specifications

  • FDA accepted [F-18] FLT products = “single IND GMP product”


Drug Master File (DMF) for FLT

DMF = Efficient CMC submission tool for manufacturers

Drug Manufacturer’s Submits Information –

Chemistry, Manufacturing and Controls (CMC) of a drug product or a component of a drug product to FDA file room to permit the FDA to review this information upon request only and in support of a specific submission


FDA Regulatory DMF Background for FLT

Five Types

  • I: Plant information

  • II: Drug substance, drug product, intermediates and material used in their manufacture

  • III: Packaging

  • IV: Excipients

  • V: Other clinical, toxicology


Key Point for FLT

CMC information must be submitted in centralized IND

  • CMC may be directly submitted in IND submission

    or

  • CMC may be submitted through a letter of cross-reference to an existing DMF filed with FDA


Letter of Authorization (LOA) - Enables FDA review of DMF for FLT

  • The DMF Holder (manufacturer) MUST submit an LOA (2 copies) to the DMF and route a separate copy to the IND Applicant

  • The Applicant submits LOA in their IND submission… the mechanism to enable review of the DMF by FDA

  • The DMF will be reviewed ONLY when it is referenced in an IND submission

  • In Europe, the LOA is called a Letter of Access


Topic 4: Imaging Standardization for FLT

Solutions

  • Clinical imaging with a standardized protocol

  • International imaging clinical site registry – hardware/software

  • Clinical trials educational programs for multicenter trials

  • Pre-clinical imaging standardization - Phantom Program

    • Oncology / CNS / Cardiovascular


SNM Imaging Phantom Program for FLT

[F-18] FLT fillable phantoms

  • Qualitative & Quantitative (SUV)

  • VA system

    • Torso: Oncology

    • Head/Brain: CNS

    • Cardiac


Plans for Future Centralized IND for FLT

  • FDG

  • FLT

  • FDOPA

  • FAZA

  • FMISO

  • Ga-68 octreotide

  • FES

  • FHDT

  • C-11 acetate


Review: Solution Topics for FLT

  • Clinical Trials Network (CTN) Sites Registry

  • Selection of IND biomarker – [F-18] FLT

  • Distributed Manufacturing of PET agents – CMC

  • Imaging Standardization


Thank You for FLT

George Mills, MD, MBA

Vice President, Medical & Regulatory Relations

Perceptive Informatics

[email protected]

Disclosures:

  • Consultant to SNM (Society of Nuclear Medicine)

  • Employee: PAREXEL/Perceptive Informatics - CRO


ad